US5453445A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Lidocaine-phenylephrine aerosol preparation
Assignee: LYNCHRIS PHARMACEUTICALS Ltd
•
Filing: 1994-05-02
•
Granted: 1995-09-26
•
Expires: 2014-05-02
Abstract
Abstract An aerosol-dispensable pharmaceutical composition consisting essentially of a combination of lidocaine free base, a pharmacologically-acceptable phenylephrine acid addition salt, and a pharmacologically-acceptable organic solvent, all dissolved in a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane of the formula CF3CH2F (HFC-134a) and 1,1,1,2,3,3,3-heptafluoropropane of the formula CF3CHFCF3 (HFC-227) or a combination of the said propellants, suitable for dispensing by means of a metered-dosage valve canister in which it is contained under pressure, avoids the necessity of premixing individual solutions by the physician just prior to use. The phenylephrine salt is preferably the hydrochloride and the solvent is preferably ethanol although other pharmacologically-acceptable solvents and pharmacologically-acceptable acid addition salts of phenylephrine may be employed. The lidocaine free base assists in solubilizing the phenylephrine salt and maintaining it in solution in the propellant.
Inventors
- 👤 Richard A. Henry
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 04:27
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/007; A61K9/0073; A61K9/008; A61K31/00; A61K31/16; A61K31/165; A61K31/167; A61K31/21; A61K31/215; A61K31/235; A61K31/24; A61K31/245; A61K31/33; A61K31/395; A61K31/41; A61K31/415; A61K31/435; A61K31/44; A61K31/445; A61K9/10; A61K9/12
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
68 words
An aerosol-dispensable pharmaceutical composition consisting essentially of a combination of lidocaine free base in an amount ranging from 5 to 20 % w/w, ethanol in an amount ranging from 5 to 20% w/w, and [the]phenylephrine acid addition salt which is the hydrochloride in an amount ranging from 0.25 to 2% w/w, all dissolved in a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane and 1,1,1,2,3,3,3-heptafluoropropane and combinations thereof.
Claim 2
Dependent Claim
68 words
An aerosol-dispensable pharmaceutical composition consisting essentially of a combination of lidocaine free base in an amount ranging from 5 to 20 % w/w, ethanol in an amount ranging from 5 to 20% w/w, and [the]phenylephrine acid addition salt which is the hydrochloride in an amount ranging from 0.25 to 2% w/w, all dissolved in a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane and 1,1,1,2,3,3,3-heptafluoropropane and combinations thereof.
Claim 3
Dependent Claim
15 words
A composition of claim 1, wherein the amount of phenylephrine hydrochloride is about 1% w/w.
Claim 4
Dependent Claim
89 words
An aerosol-dispensable pharmaceutical composition consisting essentially of a combination of lidocaine free base, a pharmacologically-acceptable phenylephrine acid addition salt which is the hydrochloride, and ethanol, all dissolved in a promellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and combinations thereof, and all under pressure in a metered-dosage valve canister which dispenses said lidocaine free base in an amount ranging from 1 to 10 mg per metered dosage unit, and dispenses said phenylephrine acid addition salt in an amount ranging from 0.1 to 1 mg per metered dosage unit.
Claim 5
Dependent Claim
89 words
An aerosol-dispensable pharmaceutical composition consisting essentially of a combination of lidocaine free base, a pharmacologically-acceptable phenylephrine acid addition salt which is the hydrochloride, and ethanol, all dissolved in a promellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and combinations thereof, and all under pressure in a metered-dosage valve canister which dispenses said lidocaine free base in an amount ranging from 1 to 10 mg per metered dosage unit, and dispenses said phenylephrine acid addition salt in an amount ranging from 0.1 to 1 mg per metered dosage unit.
Claim 6
Dependent Claim
39 words
A composition of claim 3 wherein the amount of lidocaine free base dispensed per metered dosage unit is about 2.5-5 mg and the amount of phenylephrine hydrochloride is about 0.2 mg and the ethanol solvent is about 30% w/w.
Claim 7
Dependent Claim
75 words
An aerosol-dispensable pharmaceutical composition; comprising: lidocaine present at an amount ranging from 15 to 40% w/w; a phenylephrine acid addition salt which is phenylepherine hydrochloride and is present at an amount ranging from 0.25 to 2% w/w; an organic solvent which is ethanol and is present in an amount ranging from 15 to 40% w/w; and a propellant which is 1,1,1,2-tetrafluoroethane, said lidocaine and said phenylepemhrine hydrochloride, and said ethanol being dissolved in said 1,1,1,2-tetrafluoroethane.
Claim 8
Dependent Claim
75 words
An aerosol-dispensable pharmaceutical composition; comprising: lidocaine present at an amount ranging from 15 to 40% w/w; a phenylephrine acid addition salt which is phenylepherine hydrochloride and is present at an amount ranging from 0.25 to 2% w/w; an organic solvent which is ethanol and is present in an amount ranging from 15 to 40% w/w; and a propellant which is 1,1,1,2-tetrafluoroethane, said lidocaine and said phenylepemhrine hydrochloride, and said ethanol being dissolved in said 1,1,1,2-tetrafluoroethane.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-09-25 | 1999-03-27 | 1999-09-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-09-25 | 2003-03-27 | 2003-09-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-09-25 | 2007-03-27 | 2007-09-26 | $7700.00 | Window Closed / Lapsed |